http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
직장감각저하 환자에서 바이오피드백 치료에 대한장기간 효과 및 인자 분석
정기욱 ( Kee Wook Jung ),명승재 ( Seung Jae Myung ),변정식 ( Jeong Sik Byeon ),윤인자 ( In Ja Yoon ),고정은 ( Jung Eun Ko ),서소영 ( So Young Seo ),윤순만 ( Soon Man Yoon ),도미영 ( Mi Young Do ),김도훈 ( Do Hoon Kim ),김병규 ( Be 대한장연구학회 2008 Intestinal Research Vol.6 No.1
Background/Aims: Rectal hyposensitivity (RH) has been treated with conventional biofeedback therapy (BFT), whereas the effectiveness and long term results of this therapy are not known. We aimed to investigate the effectiveness of BFT for patients with RH by conducting a retrospective review of prospectively collected data. Methods: From June 2004 to March 2007, we enrolled those RH patients who underwent BFT. BFT was performed two or three times every week. Six months after BFT, the clinical response was evaluated by subjective and objective parameters. Results: A total of 82 RH patients underwent BFT. Fifty three patients finished BFT and the other 29 patients dropped out during BFT. Thirty six patients (67.9%) showed responsiveness (R) to BFT and 17 (31.5%) showed non-responsiveness (NR). The characteristics between the two groups showed no difference, except for the “desire to defecate” volume (116.1±25.2 in the R group vs. 140.0±43.9 in the NR group, p value <0.05) and the rectoanal inhibitory reflex (RAIR) (15.6±0.5 in the R group R vs. 27.6±18.2 in the NR group, p value <0.05). The R group showed a shorter colon transit time compared to NR group. At six months after BFT, a total of 20 patients were interviewed; 15 patients answered that they still had responsiveness (75%). Conclusions: The patients with RH showed a similar BFT response to that of the constipated patients. However, the patients with a more hyposensitive rectum and a longer colonic transit showed NR to BFT, suggesting RH is an important factor in BFT responsiveness. (Intest Res 2008;6:56-69)
Laxatives 제대로 알기 ; 변비 약물 치료의 지침 - 어떤 약제를, 언제 사용해야 하는가?
신정은 ( Jeong Eun Shin ),홍경섭 ( Kyoung Sup Hong ),정기욱 ( Kee Wook Jung ),이태희 ( Tae Hee Lee ),이봉은 ( Bong Eun Lee ),박선영 ( Seon Young Park ),홍성노 ( Sung Noh Hong ),김성은 ( Seong Eun Kim ),박경식 ( Kyung Sik Park ) 대한내과학회 2015 대한내과학회지 Vol.88 No.1
To manage chronic constipation, dietary and lifestyle modifications should be tried before pharmacological intervention. Although there is no standardized treatment guideline for medical practice, the key considerations in the choice of laxative includethe treatment duration, dosing schedule, type of agent, effects and side effects of the agent, and cost. The first-line treatment is abulking or osmotic laxative. If the patient is still symptomatic, the physician can add or switch to other laxatives. Next, prucalopride,a highly selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist, could be considered. If the constipation is refractory tocombination therapy with conventional laxatives and prucalopride, patients should be referred for further evaluation, includingphysiological testing.
이정미 ( Jeong Mi Lee ),김도연 ( Do Yeon Kim ),윤인자 ( In Ja Yoon ),정기욱 ( Kee Wook Jung ) 대한내과학회 2016 대한내과학회지 Vol.90 No.2
Constipation is a common functional gastrointestinal symptom, the medical treatment of which is established. However, knowledge of diet and nutritional management for constipation is lacking. Based on current studies, fiber is effective in managing chronic constipation, but care should be taken in constipated patients with gaseous bloating. Increased fluid intake is controversial but may be beneficial, especially in conjunction with a stool-bulking agent. Other diet treatments lack high-quality evidence. A well-designed study to validate the effectiveness of diet, especially Korean diet, in the treatment of chronic constipation is needed. (Korean J Med 2016;90:111-114)
홍경섭 ( Kyoung Sup Hong ),정기욱 ( Kee Wook Jung ),이태희 ( Tae Hee Lee ),이봉은 ( Bong Eun Lee ),박선영 ( Sun Young Park ),신정은 ( Jeong Eun Shin ),김성은 ( Seong Eun Kim ),박경식 ( Kyung Sik Park ),최석채 ( Suck Chei Choi ) 대한소화기학회 2014 대한소화기학회지 Vol.64 No.3
Chronic constipation is a very common clinical problem with its prevalence of up to 14% in the general population. It is not a life-threatening disease, but since patient``s satisfaction to the treatment is known to be as low as 50%, chronic constipation still remains a clinically challenging problem. Fortunately, many new treatments have been introduced or are to be introduced in the near future. This article will review the basic concepts and the results of recent studies on the new treatments for chronic constipation. (Korean J Gastroenterol 2014;64:148-153)
홍성노 ( Sung Noh Hong ),신정은 ( Jeong Eun Shin ),홍경섭 ( Kyoung Sup Hong ),정기욱 ( Kee Wook Jung ),이태희 ( Tae Hee Lee ),이봉은 ( Bong Eun Lee ),박선영 ( Sun Young Park ),김성은 ( Seong Eun Kim ),박경식 ( Kyung Sik Park ) 대한내과학회 2015 대한내과학회지 Vol.88 No.1
A significant proportion of chronic constipation patients are dissatisfied with their treatment. Recently, a number of new medicationshave been introduced for patients refractory to conventional laxatives, such as prucalopride, lubiprostone, linaclotide, andelobixibat. Prucalopride is a novel gastrointestinal prokinetic agent that acts as a 5-hydroxytryptamine type 4 (5-HT4) agonist. Compared with older nonselective 5-HT4 agonists, the higher selectivity of prucalopride for 5-HT4 receptors can reduce the risk ofsignificant adverse cardiovascular events. Prucalopride improves stool frequency and consistency, and reduces the need for rescuemedications. Lubiprostone, a chloride channel activator, increases the secretion of intestinal fluid, improves the stool frequency andconsistency, and reduces straining. Linaclotide, a guanylate cyclase-C agonist, is effective in treating patients with chronic constipationand its effect on visceral sensitivity, as shown mainly in animal studies, provides an attractive pharmaceutical option for patients with irritable bowel syndrome with constipation. Elobixibat is an ileal sodium-dependent bile acid transporter inhibitor thatblocks the enterohepatic circulation of bile acids, increasing the bile acid concentration in the intestine, which accelerates colonictransit and softens the stool. A phase III trial of the treatment of chronic constipation and irritable bowel syndrome with constipationis underway. The clinical application of new-generation laxatives will contribute to the management of chronic constipation refractoryto conventional laxatives.
Laxatives 제대로 알기 ; 변비의 국소 치료: 관장과 좌약
김성은 ( Seong Eun Kim ),신정은 ( Jeong Eun Shin ),홍경섭 ( Kyoung Sup Hong ),이태희 ( Tae Hee Lee ),이봉은 ( Bong Eun Lee ),박선영 ( Seon Young Park ),홍성노 ( Sung Noh Hong ),정기욱 ( Kee Wook Jung ),박경식 ( Kyung Sik Park ) 대한내과학회 2015 대한내과학회지 Vol.88 No.1
The treatment for constipation should be individualized and dependent on the cause, coexisting morbidities, and patient’s cognitivestatus. Although most cases of constipation respond to conservative treatment, including dietary and life-style changes, or mildlaxatives, some patients still complain of consistent symptoms and need an assessment of defecatory dysfunction. There is insufficientevidence to support the use of enemas in chronic constipation, although many clinicians and patients find them useful andeffective for the treatment of fecal impaction when used with other modalities. In addition, suppositories can be considered as an initialtrial for the treatment of defecatory dysfunction, since they help to initiate or facilitate rectal evacuation. The routine use of enemasis typically discouraged, especially sodium phosphate enemas, although tap-water enemas seem safe for more regular use. Soapsuds enemas are not recommended due to possible rectal mucosal damage.
차동원(Dong Won Cha),김용화(Yong Hwa Kim),정기욱(Kee Wook Jeong),김창현(Chang Hyeon Kim) 한국환경영향평가학회 1998 환경영향평가 Vol.7 No.2
The first Environmental Impact Assessment(EIA) in Korea was carried out for Electric Power resource development. This study includes of the method and procedure of pre-Environmental investigation and EIA for Electric Power resource development. Through the analysis of these we make some conclusions for the improvemental and effective method of impact prediction, the environmentally sound and sustainable development of the earth(ESSD) and the collection of public opinions.
김광운 ( Gwang Un Kim ),예병덕 ( Byong Duk Ye ),변정식 ( Jeong Sik Byeon ),박환성 ( Hwan Sung Park ),옥태진 ( Tae Jin Ok ),양동훈 ( Dong Hoon Yang ),정기욱 ( Kee Wook Jung ),김경조 ( Kyung Jo Kim ),명승재 ( Seung Jae Myung ),양석 대한장연구학회 2011 Intestinal Research Vol.9 No.3
Background/Aims: With the growing volume of screening colonoscopies, the incidence of rectal carcinoids and the number of endoscopic resections for rectal carcinoids are also increasing. However, the prognosis including recurrence and metachronous lesions after endoscopic resection is unclear. Methods: The medical records of 255 patients who had undergone endoscopic resection for rectal carcinoids between October 1999 and April 2010 were retrospectively reviewed. Results: The number of males was 150 (58.8%), and the mean age was 54.1 years (range, 27-85 years). Mean tumor size was 6.9 mm. In total, 162 cases (63.5%) were treated with endoscopic mucosal resection and 93 (36.5%) were treated with endoscopic submucosal dissection. Although endoscopic complete resections were achieved in all cases, the histological examination showed 47 cases with a positive resection margin (18.4%) and three with lymphovascular invasion (1.2%). In the 54 patients with a free resection margin, who were followed for more than 12 months, abdominopelvic computed tomography and endoscopy did not show recurrence after a median of 30.5 and 36 months, respectively. Three patients with lymphovascular invasion did not show recurrence during follow-up period of 13, 30, and 37 months, respectively. Metachronous rectal carcinoids were detected in four patients at 23, 58, 61, and 89 months, respectively, after initial endoscopic resection, leading to a second endoscopic treatment. Conclusions: Small rectal carcinoids completely resected grossly and pathologically without lymphovascular invasion appear to have low probability of short-term recurrence. However, considering the slow growth rate of carcinoids, long-term follow-up for recurrence and metachronous carcinoids is required. (Intest Res 2011;9:217-224)